Yahoo Finance EN

Why ImmunityBio Stock Is Down More Than 20% Today

Mar 24, 2026 &03592424202631; 16:59 UTC finance.yahoo.com Trending 4/5

Read original on finance.yahoo.com ↗

↘

Negative for markets

Sentiment score: -75/100

High impact Immediate effect (hours)

WHAT THIS MEANS

ImmunityBio (IMNB) stock crashed >20% on fresh news 17 minutes ago, likely due to clinical trial failure, regulatory setback, or major partnership dissolution. The broad market is slightly down (-0.39%) with elevated VIX (26.41), suggesting sector-specific biotech weakness rather than systemic risk.

AI CONFIDENCE

72% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

IMNB

IMNBStock

Expected to decline

Fresh 20%+ intraday crash with no prior market reaction; likely negative catalyst (trial failure, FDA rejection, or strategic setback) not yet fully absorbed by broader biotech sector

⇅

S&P 500

^GSPCIndex

High volatility expected

S&P 500 down only -0.39% despite IMNB crash; biotech selloff isolated, no systemic contagion yet

↑

VIX

VIXIndex

Expected to rise

Fear gauge elevated at 26.41 (+0.99%); elevated volatility supports continued downside in risk assets like biotech

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

IMNB likely to test lower support levels in next 2-4 hours as news disseminates. Avoid catching falling knife; wait for stabilization or earnings/guidance clarity before re-entry. Monitor biotech ETFs (IBB, XBI) for contagion risk. [MOVE:-2.5%]

KEY SIGNALS

Fresh catalyst (17 min old) — not yet fully priced in20%+ single-day crash indicates severe negative newsElevated VIX supports continued sector weaknessBroad market resilience suggests IMNB-specific event, not systemic

SECTORS INVOLVED

HealthcareBiotechnologyPharmaceuticals

Analysis generated on Mar 24, 2026 at 17:15 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Yahoo Finance. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Why ImmunityBio Stock Is Down More Than 20% Today

RELATED INTELLIGENCE